The drugs, tested in a almost nine-month clinical trial, have performed so well that health professionals will now administer them to every patient in Congo.
While they heralded the fact that this groundbreaking research took place in the turbulent environment of eastern Congo, researchers also acknowledged that social and political factors will complicate health workers' ability to get these new drugs to patients.
"The drug mAb114 was developed using antibodies harvested from survivors of Ebola while REGN-EB3 comes from antibodies generated within mice infected with the disease", the report added.
The other two treatments, ZMapp and remdesivir, will no longer be used.
Researchers said more study is needed to nail down how well those two compounds work. In contrast, 49% on ZMapp and 53% on Remdesivir (the two earlier treatments) died, according to NIAID.
The first-ever multi-drug randomized control trial aimed at evaluating the safety and efficacy of Ebola Zaire therapeutic medications reported 2 experimental products will continue to be studied.
"The best way to end the outbreak is with a good vaccine, as well as to do good contact tracing, isolation, and then, ultimately, treatment". A vaccine is a type of medicine that improves immunity to a particular disease, as a preventative measure.
The current Ebola outbreak is now considered the second largest in history, killing at least 1,800 people.
However, attempts to contain the latest outbreak are proving hard.
Health officials have vaccinated tens of thousands of people in an attempt to stop the epidemic, but response efforts have repeatedly been thwarted by militia violence and deep mistrust among local communities. Tedros Ghebreyesus, the WHO director general, said last month that more than 200 health professionals had been attacked since January and several had been killed.
During a trial, survival rates among Ebola patients treated with REGN-EB3 and mAb114 were higher compared to other drugs.They co-function with human antibodies to neutralise Ebola virus.
The experimental drugs revealed this week will "absolutely not" cure all Ebola patients, despite showing a survival rates of as much as 90 percent in a clinical trial DR Congo, immunologist Yves Lévy, a special envoy in charge of the French Ebola response, told France Info radio. Half of those who received ZMapp died.
Dr. Anthony Fauci, director of the NIAID and one of the researchers leading the trial, said the results were "very good news" in the fight against Ebola.
"Now we can say that 90 percent can come out of treatment cured, they will start believing it and developing trust", said the 77-year-old, who was part of the team that discovered Ebola 43 years ago.
"Today's news has put us another step to saving more number of lives".
The latest trial demonstrates 'you can dramatically diminish the mortality, ' said Mr Fauci, 'but getting rid of the Ebola virus becomes a case of prevention, of how you could prevent this from spreading.
He said: 'Thanks to this trial, we are starting to understand which treatments to offer to patients in this and future outbreaks'. The study aims to enrol a total of 725.